Only two countries on earth allow drug companies to advertise prescription medications directly to the public: the United States and New Zealand. New Zealand has 5 million people and doesn’t own the world’s largest pharmaceutical market. We have 335 million patients, a drug industry that spent nearly $13.8 billion on advertising and promotion in 2023 alone, and a regulatory system that requires a physician’s signature on the product while letting Madison Avenue write the demand.
The core absurdity isn’t hard to find. Only physicians can prescribe. Yet pharmaceutical companies spend billions telling patients what to request before they ever sit down with a doctor. The FDA permits it. Federal courts treat it as protected commercial speech. Washington has decided that advertising qualifies as patient education, which says something interesting about how we view both patients and education.
The money involved clarifies everyone’s motives. Between 1997 and 2016, pharma marketing to healthcare professionals climbed from $15.6 billion to $20.3 billion, while direct-to-consumer spending rose from $2.1 billion to $9.6 billion over the same stretch. The television spots are only part of the picture. The bigger fight has always been for the person in the white coat.
Purdue Pharma is the industry’s most damning case study. Its sales force told physicians that OxyContin carried a low addiction risk—a false claim—and drove prescription volumes that created a dependent population numbering in the millions. More than 806,000 Americans died of opioid-involved overdoses between 1999 and 2023, a toll that rose 67 percent between 2017 and 2023. The legal reckoning now approaches $60 billion in settlements, including the $7.4 billion Purdue/Sackler settlement finalized in January 2025. The Sacklers are permanently banned from the U.S. opioid industry.
The law does impose requirements. Drug ads must include a major statement of risks, maintain a fair balance between benefits and harms, and avoid misleading claims. In September 2025, the Food and Drug Administration and the Department of Health and Human Services mandated clearer risk disclosures—a welcome step, however late. Every viewer knows how this resolves in practice: warm visuals, sweeping music, people apparently free of chronic pain, followed by side effects read at auctioneer pace. The rule requires disclosure. The industry has mastered making it feel like background noise.
This matters at scale because nearly everyone is medicated. The CDC reports that 49.9 percent of Americans used at least one prescription drug in the past 30 days. A March 2026 KFF poll raises the figure further: 66 percent of adults currently take at least one prescription medication, and 31 percent take four or more. This is the American population—already heavily medicated—being actively marketed to at every commercial break.
Here’s what should offend any fiscal conservative: taxpayers are subsidizing these ads. Pharmaceutical companies deduct advertising as ordinary business expenses, costing the federal government an estimated $1.5 to $1.7 billion in lost tax revenue annually. A 2023 study in the Journal of Public Economics estimated that DTC advertising drove roughly 31 percent of the rise in U.S. drug spending since 1997. Americans aren’t just watching these commercials. We’re co- financing them, then paying higher drug prices.
The standard defense is that these ads prompt patients to raise symptoms they’d otherwise ignore. Sometimes that’s true. But a system that fills medical awareness gaps through prime-time pharmaceutical marketing also assumes consumers can evaluate clinical evidence after 60 seconds of voiceover. The opioid crisis is what happens when that assumption fails at scale.
The FDA’s own enforcement record makes the structural failure plain. In the late 1990s—the same era Purdue was saturating physician offices with misleading OxyContin claims—the agency issued more than 130 enforcement letters annually to pharmaceutical advertisers. By 2023, that number had fallen to three. An executive directive in September 2025 reversed course, producing more than 100 enforcement letters almost immediately. The tools existed the entire time. No one had bothered to use them.
Reform doesn’t require a binary choice. The No Handouts for Drug Advertisements Act—introduced by Senator Josh Hawley (R-MO) and co-sponsored by Senator Jeanne Shaheen (D-NH)—eliminates the federal tax deduction for DTC pharmaceutical advertising. Stop subsidizing the commercials that drive up drug costs. The FDA has already resumed enforcement. If Congress wants to go further, the End Prescription Drug Ads Now Act offers a complete ban. We prohibited cigarette ads on television more than 50 years ago. Life went on.
My position is plain: medicine should be governed by clinical judgment, not promotional theater. The opioid crisis didn’t emerge from a vacuum—it was built one physician visit and one television commercial at a time, by an industry that understood exactly what it was doing and kept doing it. The American patient doesn’t need more pharmaceutical infotainment between innings. They need clearer information, consistent enforcement, and a healthcare system that treats them as citizens—not a target demographic. TV can sell almost anything. It shouldn’t be selling the prescription pad.
Jay Rogers is a financial professional with more than 30 years of experience in private equity, private credit, hedge funds, and wealth management. He has a BS from Northeastern University and has completed postgraduate studies at UCLA, UPENN, and Harvard. He writes about issues in finance, constitutional law, national security, human nature, and public policy.
Editor’s Note: Do you enjoy Townhall’s conservative reporting that takes on the radical Left and woke media? Support our work so that we can continue to bring you the truth.
Join Townhall VIP and use promo code FIGHT to receive 60% off your membership.
Join the conversation as a VIP Member